September 23, 2009 - After offering an amendment to close the in-office ancillary services exception for advanced medical imaging under the Stark law during the House Energy and Commerce Committee’s continued markup of H.R. 3200, America’s Affordable Health Choices Act of 2009, Rep. Anthony Weiner (D-NY) and Rep. Bruce Braley (D-IA) withdrew the offer.

September 22, 2009 —  At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Royal Philips Electronics today announced it will integrate the MAQUET Magnus surgical table with Philips’ cardiovascular X-ray systems to create an efficient hybrid operating room environment for a full range of minimally-invasive and open surgical procedures.

September 23, 2009 – Abiomed Inc. announced new clinical data from USpella, the first U.S. multicenter registry of Impella 2.5 patients evaluating the safety and feasibility of left ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention (PCI) and treatment of acute myocardial infarction (AMI).

P3T products automate protocol personalization and consistently enable improved contrast enhancement for higher quality images for CT angiography and abdominal studies. P3T Cardiac enhances CT angiography of cardiac structures, coronary arteries, chambers of the heart, thoracic and abdominal aorta, and pulmonary vasculature for pulmonary embolism (PE) studies.

September 23, 2009 – To improve the ability of physicians to provide superior patient care during interventional procedures, Toshiba America Medical Systems, Inc. has introduced its Next Generation CV-3D workstation and software package available on the Infinix-i X-ray product line.

September 22, 2009 – Physicians can now navigate even the most tortuous anatomy with greater speed and safety with the next-generation inferior vena cava (IVC) filter delivery system introduced today by Cook Medical at TCT 2009.

September 21, 2009 – Edwards Lifesciences Corp. today announced new clinical data demonstrating 100 percent freedom from structural deterioration of the Edwards SAPIEN valve at 18 months, as well as positive midterm patient outcomes resulting from the application of learnings from earlier clinical programs.

September 21, 2009 — Boston Scientific Corp. today welcomed three-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety of the Company's portfolio of drug-eluting stents, including the first-generation TAXUS Express(2) Paclitaxel-Eluting Coronary Stent System and the XIENCE V (PROMUS ) Everolimus-Eluting Coronary Stent

September 21, 2009 — Anticipating a change in the practice of interventional cardiology, Medtronic Inc.

September 22, 2009 – Cordis Corp. has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER Sirolimus-Eluting Coronary Stent – the 2.25 mm CYPHER – which is indicated for treatment of coronary blockages in small vessels.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now